Highlights of clinical research on liver transplantation in China of 2023
10.3969/j.issn.1674-7445.2024063
- VernacularTitle:2023年中国肝移植临床研究年度盘点
- Author:
Fangfei WANG
1
;
Qiang HE
1
Author Information
1. Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
- Publication Type:AcademicSummary
- Keywords:
Liver transplantation;
Rejection;
Ischemia-reperfusion injury;
Infection;
Delayed graft function;
Biliary complication;
Hepatocellular carcinoma;
Chronic kidney disease
- From:
Organ Transplantation
2024;15(3):377-382
- CountryChina
- Language:Chinese
-
Abstract:
As a mature organ transplantation, liver transplantation has become the optimal treatment for end-stage liver disease, which can improve the quality of life of recipients. However, liver transplantation still faces multiple challenges, such as rejection, infection, biliary complications, delayed graft function, ischemia-reperfusion injury, recurrence of hepatocellular carcinoma after liver transplantation, kidney-related diseases after transplantation, and donor shortage, etc., which remain to be improved and urgently resolved. With persistent attempts and experience accumulated by Chinese experts and scholars, these problems related to liver transplantation have been gradually resolved year by year. In 2023, liver transplantation teams in China have achieved a series of significant progresses in the field of clinical research. In this article, clinical frontiers and novel technological progresses in the field of liver transplantation in 2023 were reviewed, and the achievements of clinical liver transplantation in China in 2023 were summarized, aiming to provide novel ideas for promoting further development of liver transplantation in China.
